NCT05192798: Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have previously received antitumor systemic therapy for metastasis

Comments are closed.

Up ↑